Lung Squamous Cell Carcinoma Clinical Trial
Official title:
An Open-label, Single-arm Clinical Study to Evaluate the Efficacy of Afatinib in Advanced Lung Squamous Cell Carcinoma With EGFR Sensitive Mutation
This is an open-label, sing-arm, single site, phase IV clinical study. The main objective is to evaluate the efficacy of afatinib in LSQC patients with EGFR sensitive mutation, and to explore the clinical factors which might be predictive for the effectiveness in LSQC.
This is an open-label, sing-arm phase IV clinical study which will recruit about 20 patients
in China.
The main objective of this study is to evaluate the efficacy of afatinib in LSQC patients
with EGFR sensitive mutation, and to explore the clinical factors which might be predictive
for the effectiveness in LSQC.
Target patient population:Locally advanced (IIIB) or metastatic (stage IV)
immunohistochemistry (IHC)-verified Lung squamous cell carcinoma (LSQC) with EGFR sensitive
mutation patients, whom previously untreated or received platinum-based doublet chemotherapy
as first-line treatment with subsequent disease progression, and had to be eligible for
second-line treatment.
Investigational product, the dose and administration method: Afatinib is a member of the
second generation TKIs, which binds irreversibly to the erbB family of receptors. Afatinib
will be administrated orally with the starting dose of 40 mg tablets, once per day. If
patients can't tolerate drug related AEs with 40mg, patients can receive 30mg once per day
after AEs recovered to Grade 0-1 (CTCAE 5.0).
Study assessment: The collected data include the patient's demographic characteristics,
information needed to determine whether the patient is eligible (including medical history,
attributes of previous and current disease, and EGFR mutation status in tumor tissues),
efficacy of objective response rate(ORR), progression-free survival (PFS), overall survival
(OS), and safety (including serious adverse events and dose change-induced adverse events).
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Withdrawn |
NCT04267913 -
Testing of TAK228 (MLN0128, Sapanisertib) Plus Docetaxel to the Usual Standard of Care for Advanced Squamous Cell Lung Cancer (A Lung-MAP Treatment Trial)
|
Phase 2 | |
| Not yet recruiting |
NCT03725423 -
Apatinib for Advanced Lung Squmamous Carcinoma
|
Phase 4 | |
| Recruiting |
NCT06255197 -
Characteristics, Treatment Patterns and Outcomes for Patients With Surgically Resected Lung Cancers
|
||
| Active, not recruiting |
NCT04152018 -
Study of PF-06940434 in Patients With Advanced or Metastatic Solid Tumors.
|
Phase 1 | |
| Recruiting |
NCT05778253 -
The Role of ctDNA Testing Plus AI-based Pathology in Resectable LSCC
|
||
| Recruiting |
NCT02876978 -
Anti-GPC3 CAR T for Recurrent or Refractory Lung Squamous Cell Carcinoma
|
Phase 1 | |
| Completed |
NCT01807546 -
Oral Rigosertib for Squamous Cell Carcinoma
|
Phase 2 | |
| Active, not recruiting |
NCT01386385 -
Veliparib With or Without Radiation Therapy, Carboplatin, and Paclitaxel in Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT00334815 -
Combination Chemotherapy, Radiation Therapy, and Bevacizumab in Treating Patients With Newly Diagnosed Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery
|
Phase 2 | |
| Recruiting |
NCT05782764 -
A Study of Endostar Combined With Chemotherapy and Immunotherapy in Lung Squamous Cell Carcinom
|
Phase 4 | |
| Recruiting |
NCT05010330 -
Identify Prognostic Biomarkers of Lung Cancer
|
||
| Recruiting |
NCT05024266 -
Tislelizumab Combined With Chemotherapy as Neoadjuvant Therapy for Stage IIIA-IIIB (N2) Lung Squamous Cell Carcinoma
|
Phase 2 | |
| Recruiting |
NCT04802876 -
Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients With PD1-high mRNA Expressing Tumors
|
Phase 2 |